Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Mochida Pharmaceutical Co., Ltd.

Mochida Paraceuticals Co., Ltd.

Mochida Pharmacuetical Co., Ltd.

Liangqin Guo

Shuwen He

Yongxin Han

Ravi P Nargund

Alexander Pasternak

Hongjun Zhang

Ting Zhang

Joseph A Kozlowski

Wensheng Yu

Zhixiong Ye

Xavier Fradera

Dane James Clausen

Qinglin Pu

Jian Liu

Derun Li

Li Xiao

Xianhai Huang

Kun Liu

Deping Wang

Ronald M Kim

Guoqing Li

Yi-Heng Chen

Walter Won

Tianying Jian

Iyassu K Sebhat

William J Greenlee

Arthur A Patchett

Lihu Yang

Samuel Chackalamannil

James M Balkovec

Philippe G Nantermet

Mark E Layton

Thomas J Greshock

Harold B Wood

Abdelghani Achab

Ping Chen

Anthony J Roecker

Rajan Anand

Cameron James Smith

James J Mulhearn

Gang Zhou

Feng Ye

Yili Chen

John Qiang Tan

Tomokazu Hirabayashi

Hua Zhou

Hubert B Josien

Feroze Ujjainwalla

Michael Man-Chu Lo

Thomas Joseph Tucker

David L Sloman

Fa-Xiang Ding

Kevin Tyler Chapman

James R Tata

Raman Kumar Bakshi

Purakkattle J Biju

Yongqi Deng

Michael J Kelly, Iii

Abbas M Walji

Edward C Sherer

Rui Zhang

Khaled J Barakat

William K Hagmann

Shrenik K Shah

Changyou Zhou

Jongwon Lim

Dong Xiao

Younong Yu

David B Johnston

James J Perkins

Jason M Cox

Christopher S Burgey

Hong Liu

Jonathan R Young

Zhi-Cai Shi

Gregori J Morriello

Tin-Yau Chan

Alan W Hruza

Helen Y Chen

Bing Li

Nunzio Sciammetta

Dongfang Meng

Junying Zheng

Meredeth Ann McGowan

Christopher James Bungard

Jiayi Xu

Quang T Truong

Min K Park

John E Stelmach

David Jonathan Bennett

Min Lu

Mehul F Patel

Meng Hsin Chen

Brenda L Palucki

Scott C Berk

Zhong Lai

Indu T Bharathan

Hiroshi Nagasue

Andreas Verras

Ravi Kurukulasuriya

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Disclosed are compounds of Formula (I), Formula (II), or a salt thereof: Formula (I) Formula (II) which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula (I), Formula (II) or their salts, and methods of treating pain disorders, cough, and itch using the same.

4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels

Disclosed are compounds of Formula A, or a pharmaceutically acceptable salt thereof: where A, X, R, and Rare as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.

PCSK9 antagonist compounds

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Arylalkyl pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors

Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Formula (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

[1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors

Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted N'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase IDO inhibitors

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Disclosed are compounds of Formula A, or a salt thereof: Formula (A), wherein: Het, Q and Rto Rare defined herein, which compounds have properties for blocking Na1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating cough, itch, acute pain and neuropathic pain disorders using the same. 

Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels

Compounds of Formula I, or a pharmaceutically acceptable salt, solvate or hydrate thereof: (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted sulfoximine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Compounds as indoleamine 2,3-dioxygenase inhibitors

Disclosed are compounds of Formula A, or a salt thereof, where Q, X, R1 and R2 are as defined herein, which compounds have properties for inhibiting Na1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating pain (acute, post-operative, neuropathic), or cough or itch disorders using the same. 

Growing community of inventors

Edison, NJ, United States of America

Liangqin Guo